Ateam of researchers from the University of Toronto and Oxford Population Health have shed some light on the interpretation ...

Co. Ltd. has obtained IND clearance from the FDA for NTS-231, a covalent allosteric molecular glue degrader of NRF2.

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare autosomal-recessive cholestatic liver disease caused ...

Sola Biosciences Japan GK, the wholly owned Japanese subsidiary of Sola Biosciences Inc., has been awarded a grant of ...

Thalia Therapeutics plc has completed initial chemistry synthesis of siRNA gene-silencing medicines for its cardiovascular program, THAT-002. THAT-002 is being developed as a potentially long-duration ...

Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy with frequent relapses and poor outcomes despite advances in chemotherapy, hematopoietic stem cell transplantation ...

Voltage-gated (Kv) potassium channels play essential roles in neuronal physiology, and their dysfunction can lead to several pathologies. Among them, mutations in the silent modulatory Kv8.2 subunit ...

Radionetics Oncology Inc. has described new peptide-drug conjugates comprising peptides targeting proteinase-activated receptor 2 (F2RL1; PAR2) covalently linked to a radiolabeled metal chelator ...

Investigators from the University of Innsbruck recently presented data regarding StU-035, an azole-photosensitizer conjugate ...

Kitasato Institute and Kowa Co. Ltd. have patented new N-methylhydroxypyridone glycoside derivatives reported to be useful for the treatment of Clostridioides difficile infection.

The development of noncovalent KRAS inhibitors has remained challenging, resulting in molecules with high molecular weight and limited bioavailability. At the American Association for Cancer Research ...

At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma ...